詹智斌 王冬菊 宋强

[摘要] 目的 分析利拉鲁肽联合二甲双胍治疗2型糖尿病的临床疗效。方法 取70例该院的2型糖尿病患者进行观察，患者在2018年1月—2020年2月期间入组，使用计算机分组方式将患者分为对照组和观察组，对照组使用二甲双胍治疗，观察组联合利拉鲁肽治疗，对比两组的疗效、血糖治疗以及不良反应。结果 观察组患者治疗有效率数据是94.29%（33例），较之对照组的74.29%（26例）更高，数据差异有统计学意義（χ2=5.285，P<0.05）;观察组干预后空腹血糖是（5.8±1.3）mmol/L，餐后2 h血糖水平是（8.1±0.3）mmol/L，糖化血红蛋白为（6.1±0.6）%，数据均低于对照组，且差异有统计学意义（t=4.516、9.090、7.483，P<0.05）;观察组不良反应发生率为8.57%（3例），和对照组的11.43%（4例）比较差异无统计学意义（χ2=0.159，P>0.05）。结论 利拉鲁肽联合二甲双胍治疗2型糖尿病可以降低患者血糖指标，起到理想的治疗效果，而且不良反应少，用药比较安全，综合疗效优于单独用药。

[关键词] 利拉鲁肽;二甲双胍;2型糖尿病;临床疗效;血糖;安全性

[中图分类号] R58          [文献标识码] A          [文章编号] 1672-4062（2020）08（b）-0092-03

[Abstract] Objective To analyze the clinical efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes. Methods 70 patients with type 2 diabetes in the hospital were observed. The patients were enrolled from January 2018 to February 2020. The patients were divided into a control group and an observation group using computer grouping. The control group was treated with metformin. The observation group was combined with liraglutide therapy to compare the efficacy， blood glucose treatment， and adverse reactions of the two groups. Results The treatment efficiency data of the observation group was 94.29% （33 cases）， which was higher than 74.29% （26 cases） of the control group. The data were significantly different（χ2=5.285，P<0.05）; fasting blood glucose after intervention in the observation group was （5.8±1.3） mmol/L， 2 h postprandial blood glucose level was （8.1±0.3） mmol/L， glycated hemoglobin was （6.1±0.6）%， the data were lower than the control group， and the difference was statistically significant（t=4.516，9.090，7.483，P<0.05）; the incidence of adverse reactions in the observation group was 8.57% （3 cases）， which was not statistically significantly different from 11.43% （4 cases） in the control group（χ2=0.159，P>0.05）. Conclusion Liraglutide combined with metformin in the treatment of type 2 diabetes can lower the blood glucose index of patients and play an ideal therapeutic effect， and it has fewer adverse reactions， the drug is safer， and the comprehensive effect is better than the drug alone.

[Key words] Liraglutide; Metformin; Type 2 diabetes; Clinical efficacy; Blood glucose; Safety

糖尿病是一种因饮食、环境或是遗传等因素导致的慢性内分泌疾病，以胰岛素分泌异常为主要的病理表现，可导致患者血糖升高、形体消瘦，影响全身糖代谢，并逐步对肝脏以及其他躯体脏器功能产生损害[1]。该病目前没有根治方式，一般依靠饮食控制和终身用药进行治疗。由于疾病病程迁延，并发症较多，因此在发病后必须采取积极的治疗措施以延缓病程发展，减少并发症，提高患者的生存质量[2]。目前，临床中普遍采用的是多种药物联合使用，可以达到比较理想的质量效果。故此，文章分析了利拉鲁肽联合二甲双胍治疗2型糖尿病的临床疗效，并选取了2018年1月—2020年2月期间70例该院的2型糖尿病患者进行观察，报道如下。……